All News

Youths with depression had about twice the odds of prescription drug misuse and 4 times the odds of use disorder, compared with peers without depression.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.

Anti-CGRP antibody exposure near conception was linked to higher spontaneous abortion risk in migraine, while propranolol was not, a cohort study found.

Combined MRI and ultrasound raised sensitivity for bowel and uterosacral ligament endometriosis but reduced specificity in a prospective cohort study.

Asia-Pacific Delphi Consensus updates alopecia areata clinical guidelines for trichoscopy, SALT Score severity, and first-line JAK inhibitors.

Experts spot idiopathic hypersomnia when tests miss it, using symptom scales, targeted questions, wearables, and shared treatment choices.

Deep learning digital pathology predicts mantle cell lymphoma outcomes from routine biopsy slides, matching biomarkers to improve MIPI risk stratification.

In 179 patients with essential thrombocythemia, higher ropeginterferon alfa-2b exposure was linked to larger JAK2V617F allele burden drops at 6 months.

FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.

Asian expert consensus updates mantle cell lymphoma treatment guidelines, highlighting uneven BTK inhibitor, ibrutinib and CAR T-cell access across Asia.

At ASN Kidney Week 2026, experts said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.

Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.

ASN Kidney Week 2026 experts discussed GLP-1 RAs alongside lifestyle care, global access, and bariatric surgery for obesity in chronic kidney disease.